Somewhere in England this week, a family caring for a relative with early Alzheimer's is doing the arithmetic that thousands of others have done since August 2024. Lecanemab exists. It has been licensed. It slows the disease. And for two years it has sat just out of reach, judged by the National Institute for Health and Care Excellence to cost more than the benefit it delivers is worth. That judgment has now shifted, not because the drug changed, but because the numbers used to weigh it did.

The detail that ought to trouble anyone who follows how the NHS rations care is not that Eisai and Lilly have been invited into commercial talks. Manufacturers appeal unfavourable rulings routinely, and NICE occasionally revises its position under pressure. What is unusual is the nature of the revision. The original appraisal assumed that moving a patient from mild cognitive impairment to severe dementia reduced a carer's quality of life by roughly four per cent, a figure that always looked difficult to defend to anyone who has actually done that caring. NICE has now accepted that this understated the toll considerably, alongside a separate concession that the projected cost of administering fortnightly infusions had been overstated by as much as six times. Two inputs, both now judged wrong in the same direction, both moving in favour of approval.

There is a reasonable, technical explanation for this. Cost-effectiveness modelling depends on assumptions that are contestable by design, and an appeals process exists precisely to test them. But the scale and convenience of the correction invite a harder question about how NICE arrives at its numbers in the first place, and how much weight manufacturers' objections carry when a drug has enough political and public sympathy behind it. Dementia has that sympathy in abundance. The next expensive, marginal-benefit therapy to reach appraisal may not.

That matters because lecanemab is not a one-off. It is the leading edge of a category of treatments, disease-modifying rather than curative, expensive to deliver, and measured in months of slowed decline rather than years of restored health, that will recur across neurodegenerative and metabolic disease over the coming decade. If the lesson manufacturers take from this episode is that NICE's assumptions can be renegotiated through sustained appeal and public pressure, every future submission will be built around contesting the model rather than accepting its verdict. NICE's credibility rests on the perception that its thresholds are fixed points, not opening bids.

The politics sit awkwardly for a government that has staked real capital on fiscal seriousness in health. Andy Burnham's administration, with Yvette Cooper at the Department of Health and Social Care, inherited an NHS whose financial settlement leaves little room for open-ended commitments, and has been explicit that not every effective treatment can be funded regardless of cost. Reaching a commercial deal for a drug carrying a list price of £20,000 a year, even at a steep discount, sits uneasily beside that message. Handled through quiet negotiation rather than public reversal, the tension is manageable. Handled clumsily, it becomes evidence that fiscal discipline bends once a sufficiently sympathetic patient group and a sufficiently determined manufacturer apply pressure together.

There is also a delivery problem that the price alone does not solve. Fortnightly hospital infusions require diagnostic capacity, monitoring for side effects including brain swelling, and specialist staff that many memory clinics do not currently have in sufficient numbers. Eisai's self-administered, home-injected version, awaiting a UK regulatory decision, could ease that considerably, but a home-administration model brings its own governance and safety questions that NICE has not yet had to price in.

None of this argues that the deal should not proceed. Slowing the decline of a devastating disease is worth pursuing, and revising a flawed assumption about carer burden is defensible on its own terms. But NICE's willingness to reopen settled arithmetic under appeal, twice, in the same case, sets a precedent that the next manufacturer with a marginal drug and a well-organised patient charity will remember. The NHS's rationing framework only holds if its numbers mean what they say.